Venmax Drugs

Which are the latest news on Venmax Drugs?

Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?

As of 28-Jun, Venmax Drugs & Pharmaceuticals Ltd is facing a significant decline in its stock price, currently at Rs 18.26, down 8.1% over the past week and 26.81% year-to-date. The stock's poor performance relative to the market, high volatility, and weak fundamentals indicate a lack of investor confidence and a bearish trend.

As of 28-Jun, Venmax Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 18.26, which reflects a change of -1.61 (-8.1%). The stock has underperformed significantly compared to the benchmark Sensex, which has only decreased by -0.40% over the same period. <BR><BR>In the past week, the stock has dropped by 8.10%, and over the past month, it has seen a substantial decline of 23.57%. Year-to-date, the stock is down 26.81%, and it has also underperformed over the last year with a decrease of 29.96%. This consistent downward trend indicates a lack of investor confidence and poor performance relative to the broader market.<BR><BR>Today's trading session has highlighted several concerning factors. The stock has underperformed its sector by 7.82% and has fallen after two consecutive days of gains. It reached an intraday low of Rs 17.65, marking a significant drop of 11.17%. The stock has exhibited high volatility, with an intraday volatility of 5.92%, and it is trading below all key moving averages, indicating a bearish trend.<BR><BR>Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 44.74% compared to the five-day average. This suggests that fewer investors are willing to hold the stock, further contributing to its decline in price.<BR><BR>The company's fundamentals also paint a bleak picture. With a low return on equity (ROE) of 0.09% and a high debt-to-EBITDA ratio, the company is struggling to demonstrate long-term growth potential. The stock's valuation is considered very expensive with a price-to-book value of 4.8, despite a 26% increase in profits over the past year. This disconnect between stock performance and profit growth, combined with poor long-term performance metrics, supports the conclusion that the stock is in a downward trajectory.

How big is Venmax Drugs?

As of 10th June, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 24.00 Cr, with net sales of 8.02 Cr and a net profit of 0.20 Cr over the latest four quarters.

As of 10th June, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Venmax Drugs reported net sales of 8.02 Cr and a net profit of 0.20 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 4.41 Cr and total assets of 5.17 Cr.

Who are in the management team of Venmax Drugs?

The management team of Venmax Drugs includes Rajkumar Rai (Managing Director), N Krishnaiah (Non Executive Director), A Ramakrishnaiah (Non Executive Independent Director), N V Narender (Chairman), and Gali Satya Venkata Divya Jyothi (Non Executive Independent Director).

The management team of Venmax Drugs includes the following individuals:<BR><BR>1. **Rajkumar Rai** - Managing Director<BR>2. **N Krishnaiah** - Non Executive Director<BR>3. **A Ramakrishnaiah** - Non Executive Independent Director<BR>4. **N V Narender** - Chairman<BR>5. **Gali Satya Venkata Divya Jyothi** - Non Executive Independent Director<BR><BR>If you have any more questions about Venmax Drugs or its operations, feel free to ask!

Who are the peers of the Venmax Drugs?

Venmax Drugs' peers include Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., Ishita Drugs, Shree Ganesh Bio, Centuple Global, Dipna Pharmachem, Medicamen Organ, and Mono Pharmacare. Management and growth risks are generally below average for most peers, with Centuple Global showing the highest 1-year return at 110.47%, while Venmax Drugs has a return of -25.15%.

Peers: The peers of Venmax Drugs are Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., Ishita Drugs, Shree Ganesh Bio, Centuple Global, Cian Healthcare, Dipna Pharmachem, Medicamen Organ, and Mono Pharmacare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Chandra Bhagat, Guj. Terce Labs., Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Cian Healthcare, Dipna Pharmachem, Medicamen Organ, and Mono Pharmacare, while Average management risk is found at Welcure Drugs. Good management risk is noted at Centuple Global. Below Average growth is seen at Chandra Bhagat, Guj. Terce Labs., Venmax Drugs, Ishita Drugs, Cian Healthcare, Medicamen Organ, and Mono Pharmacare, while Average growth is observed at Venmax Drugs, and Excellent growth is noted at Dipna Pharmachem. Good growth is found at Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, and Centuple Global. Below Average capital structure is present at Chandra Bhagat, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Dipna Pharmachem, Medicamen Organ, and Mono Pharmacare, while Good capital structure is noted at Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, and Centuple Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centuple Global at 110.47%, while the peer with the lowest is Welcure Drugs at -74.75%. Venmax Drugs has a 1-year return of -25.15%, which is higher than Welcure Drugs but lower than Centuple Global. Additionally, the six-month returns are negative for Welcure Drugs, Guj. Terce Labs., Centuple Global, Dipna Pharmachem, and Medicamen Organ.

What does Venmax Drugs do?

Venmax Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 4 Cr and no profit for the quarter ending March 2026. The company has a market cap of INR 24 Cr and key metrics include a P/E ratio of 113.00 and a return on equity of 4.56%.

Overview:<BR>Venmax Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was initially incorporated in 1998 as "Yenkay Medico Private Limited" and underwent several name changes, becoming a Public Limited Company in 1995. The latest quarter reported for sales and profit is March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 113.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.56<BR>- Return on Equity: 4.56%<BR>- Price to Book: 5.50<BR><BR>Contact Details:<BR>Address: H.No 1-140 Rajeswari Warehouse, Kompally Quthbullapur Hyderabad Telangana : 500014<BR>Email: venmaxdrugs@gmail.com<BR>Website: http://www.venmaxdrugs.com

Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?

Venmax Drugs & Pharmaceuticals Ltd's latest results show impressive revenue growth of 1,093.94% year-over-year, but profitability is a concern with a net profit decline of 85.90% and low operating margins. Additionally, a significant drop in promoter shareholding raises questions about the company's financial health and sustainability.

The latest results for Venmax Drugs & Pharmaceuticals Ltd present a mixed picture. On one hand, the company has achieved remarkable revenue growth, with net sales soaring by 1,093.94% year-over-year, increasing from ₹0.33 crores to ₹3.94 crores in Q4 FY26. This significant top-line expansion is a positive indicator of the company's ability to scale its operations.<BR><BR>However, the profitability aspect raises concerns. The net profit for the quarter was only ₹0.11 crores, which represents a staggering decline of 85.90% compared to the same quarter last year. The operating margin is also very low at just 0.25%, indicating that the company is struggling to convert its revenue into profit effectively. Additionally, a substantial portion of the operating profit (90%) came from other income rather than core pharmaceutical operations, which questions the sustainability of its earnings.<BR><BR>The company's financial health is further complicated by a significant drop in promoter shareholding, which has decreased from 23.13% to 13.80% over the past year, signaling a lack of confidence from insiders. Overall, while the revenue growth is impressive, the declining profitability, reliance on non-operational income, and promoter confidence issues suggest that the results are more concerning than positive.

Should I buy, sell or hold Venmax Drugs & Pharmaceuticals Ltd?

When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?

The next results date for Venmax Drugs & Pharmaceuticals Ltd is 14 May 2026.

The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026.

How has been the historical performance of Venmax Drugs?

Venmax Drugs has experienced significant fluctuations in financial performance, with net sales increasing to 0.81 Cr in March 2025 from 0.00 Cr in the previous year, but overall profitability declined, resulting in a negative profit after tax of -0.01 Cr. Despite growth in sales and total assets, the company faces challenges in maintaining profitability due to rising expenditures and liabilities.

Answer:<BR>The historical performance of Venmax Drugs shows significant fluctuations in its financial metrics over the years, particularly in net sales, operating profit, and overall profitability.<BR><BR>Breakdown:<BR>Venmax Drugs reported net sales of 0.81 Cr in March 2025, a notable increase from 0.00 Cr in March 2024, but still below the 2.55 Cr recorded in March 2015. The total operating income followed a similar trend, reaching 0.81 Cr in March 2025, compared to 0.00 Cr in the previous year. However, total expenditure surged to 1.86 Cr in March 2025, up from 0.10 Cr in March 2024, leading to an operating profit (PBDIT) of 0.00 Cr in March 2025, a decline from 0.10 Cr in March 2024. The profit before tax was slightly negative at -0.01 Cr in March 2025, contrasting with a profit of 0.09 Cr in March 2024. Consequently, the profit after tax also fell to -0.01 Cr in March 2025 from 0.06 Cr in March 2024. The company's total assets increased to 5.17 Cr in March 2025 from 0.08 Cr in March 2024, while total liabilities also rose to 5.17 Cr in March 2025, reflecting a significant increase in short-term borrowings. The cash flow from operating activities was negative at -2.00 Cr in March 2025, although the net cash inflow was positive at 2.00 Cr due to financing activities. Overall, the financial performance of Venmax Drugs indicates challenges in maintaining profitability despite some growth in sales and assets.

Who are the top shareholders of the Venmax Drugs?

The top shareholders of Venmax Drugs are Venkat Narender Nuka with 17.69%, and Percy Homi Italia with 8.9%. Individual investors own 65.24% of the company, with no institutional holdings or pledged promoter shares.

The top shareholders of Venmax Drugs include Venkat Narender Nuka, who holds the highest promoter stake at 17.69%. The highest public shareholder is Percy Homi Italia, with a holding of 8.9%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Is Venmax Drugs overvalued or undervalued?

As of December 2, 2024, Venmax Drugs is considered a risky investment due to its overvaluation, reflected in a PE ratio of -12.77, an EV to EBITDA of -9.85, a ROCE of -53.54%, and a recent stock decline of 10.22%, contrasting with the Sensex's 3.83% increase.

As of 2 December 2024, the valuation grade for Venmax Drugs has moved from does not qualify to risky. Based on the analysis, the company is considered overvalued. Key ratios include a PE ratio of -12.77, an EV to EBITDA of -9.85, and a ROCE of -53.54%. <BR><BR>In comparison to its peers, Venmax Drugs has a significantly lower PE ratio than Sun Pharma, which stands at 35.25, and a much less favorable EV to EBITDA ratio compared to Cipla's 15.93. The company's negative performance metrics, alongside its recent stock decline of 10.22% over the past month against a 3.83% increase in the Sensex, further reinforce the notion that Venmax Drugs is not a sound investment at its current valuation.

What is the technical trend for Venmax Drugs?

As of April 1, 2025, Venmax Drugs shows a mildly bullish trend, supported by daily moving averages, but mixed signals from weekly and monthly indicators suggest a cautious outlook.

As of 1 April 2025, the technical trend for Venmax Drugs has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly MACD remains bullish, but the monthly RSI is bearish, indicating weakness in momentum. Overall, the mixed signals from various time frames suggest a cautious outlook despite the mildly bullish trend.

Has Venmax Drugs declared dividend?

No Dividend History Available